Informations sur le produit
SAR125844 is a potent inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR). It has been shown to inhibit tumor growth in animal models and inhibit cell proliferation in cancer cells. SAR125844 has been evaluated in clinical studies for the treatment of patients with prostate cancer, which is resistant to imatinib. The drug was found to be safe and well tolerated at doses up to 800 mg/day. Clinical response rates were observed in some patients who had experienced disease progression while on other therapies. SAR125844 inhibits tumor growth by targeting EGFR, which is an important cellular pathway that promotes cell proliferation and survival.
Propriétés chimiques
Question d’ordre technique sur : 3D-RUB74346 SAR125844
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
